Loading...
•
Jun 30, 2024
Corcept Therapeutics Q2 2024 Earnings Report
Corcept Therapeutics reported second quarter financial results and provided a corporate update.
Key Takeaways
Corcept Therapeutics reported a strong second quarter with revenue of $163.8 million, a 39% increase compared to the same period in 2023. The company also increased its 2024 revenue guidance to $640 - $670 million. Net income was $35.5 million, resulting in diluted earnings per share of $0.32.
Revenue increased by 39% compared to the same period in 2023, reaching $163.8 million.
2024 revenue guidance was increased from $620 - $650 million to $640 - $670 million.
Net income per common share (diluted) was $0.32, compared to $0.25 in the second quarter of 2023.
Cash and investments totaled $492.5 million as of June 30, 2024.
Revenue by Segment
Forward Guidance
Corcept Therapeutics increased its 2024 revenue guidance to $640 - $670 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...